Hydroxyquinoline

Quick links to important sections

Hydroxyquinoline

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hydroxyquinoline

Quick Facts

Property Description
Active ingredient Hydroxyquinoline (8-quinolinol)
Form Solution, powder, topical preparation, suppository
Pharmacological class Antiseptic, Antimicrobial agent
General purpose Local sanitation and microbial control
Origin Synthetic compound (quinoline derivative)

What is Hydroxyquinoline and What Type of Agent is It?

Hydroxyquinoline is a synthetic compound used broadly as an Antiseptic and Antimicrobial agent to prevent or reduce the growth of various microbes. It is chemically identified as 8-Hydroxyquinoline or 8-quinolinol (C9H7NO), and belongs to the quinoline derivative class of drugs. This compound is a manufactured substance rather than a naturally derived one. Its fundamental classification defines its purpose in maintaining local hygiene and sanitation by controlling microbial proliferation in various settings. This class of agent is often clinically recognized for its versatility in different physical forms compared to highly specific prescription antibiotics.


Composition, Forms, and General Purpose

The active component, 8-Hydroxyquinoline, functions by acting as a metal-chelating agent, meaning it binds to vital metal ions like iron and copper that microorganisms require for their essential internal processes, thereby inhibiting their growth. This action supports its antifungal and bacteriostatic properties. Hydroxyquinoline is incorporated into several dosage forms to accommodate different application needs, including sterile solutions for washes, fine powders, topical preparations, and suppositories for local delivery. This versatility allows for varied routes of administration, such as topical or vaginal use. The compound's general therapeutic purpose is to efficiently reduce and inhibit microbial growth, making it a foundational element in over-the-counter (OTC) antiseptic products. Hydroxyquinoline exhibits specific activity as a fungistatic agent against certain types of fungi.

What side effects are possible with Hydroxyquinoline?

Possible Side Effects and Safety Information

The regulatory information for Hydroxyquinoline (8-quinolinol), which functions as a local antiseptic agent, defines its safety profile based on inherent chemical hazards rather than the standard clinical adverse reaction categories seen with systemic prescription drugs. The official documentation identifies specific risks associated with exposure.


Regulatory Safety Classifications and Hazards

The safety profile is structured by chemical hazard classifications from authoritative bodies such as the European Chemicals Agency (ECHA), outlining immediate and serious risks.

Classification Area Officially Documented Hazard
Local Effects Classified for potential to cause serious eye damage and may cause an allergic skin reaction (skin sensitisation).
Systemic Toxicity Classified for acute toxicity if swallowed, indicating a serious systemic hazard upon ingestion.
Reproductive Safety Officially classified as Toxic to Reproduction (Category 1B), with the statement that it may damage fertility or the unborn child.

Population-Specific and Serious Safety Constraints

The compound is officially classified as a Reproductive Toxin, which imposes a significant constraint on its handling and use, particularly in situations where exposure to a developing fetus or reproductive organs is possible. The most serious local hazard documented is the potential for serious eye damage, which carries a risk of permanent injury. Due to its classification for acute toxicity, the compound's use is subject to restrictions requiring that all safety precautions be understood prior to handling or application.

This structure defines the risks by focusing on specific organ hazards and high-level safety constraints, which is distinct from the frequency-based side effect lists of prescription medications.

Overdose and Emergency Response

Overdose Manifestations and When to Seek Help

Overdose with Hydroxyquinoline is defined by regulatory authorities as overexposure that results in systemic toxicity, typically following massive or accidental oral ingestion of the product.

Manifestation Profile Officially Documented Status
Systemic Symptoms Gastrointestinal distress (nausea, vomiting, abdominal pain) and Central Nervous System (CNS) effects such as dizziness or tremor.
Severe Outcomes Life-threatening risks, including convulsions, cardiovascular collapse, and potential renal or hepatic injury.
Specific Toxicity Potential for visual disturbances or peripheral neuropathy is documented for significant systemic exposure to quinoline compounds.
Population Risk Pediatric patients and individuals with pre-existing renal impairment are noted to have an increased risk of severe effects.

Regulator-Mandated Emergency Actions

In all suspected cases of overdose, official guidance requires the individual to seek immediate medical attention and contact emergency services. Urgent care is necessary if symptoms involve severe CNS changes, difficulty breathing, or signs of organ injury. Management is officially described as symptomatic and supportive, as no specific antidote is known for Hydroxyquinoline toxicity. Regulatory protocols mandate necessary observation measures, including continuous cardiac monitoring and assessment of neurological, renal, and hepatic function, often requiring hospital monitoring.

Therapeutic Uses of Hydroxyquinoline

Hydroxyquinoline is primarily used as an antimicrobial agent to provide symptomatic relief across localized and internal conditions driven by microbial or parasitic factors. It is applied in addressing symptomatic discomfort and provides supportive relief when symptoms interfere with routine activities in two distinct domains.

This class of agent is relevant for conditions presenting with symptomatic discomfort and where additional symptomatic support is needed.

Supporting Skin and Mucosal Comfort

This agent is commonly applied in addressing symptoms related to inflammatory or irritative states, such as redness, itching, and burning, which are often associated with minor wounds or chronic skin issues like eczema. The use of this agent supports improved comfort during periods of heightened symptoms associated with persistent skin manifestations.

Management of Intestinal and Localized Infections

Hydroxyquinoline is considered relevant for managing gastrointestinal symptoms that create noticeable physiological strain during an acute episode. It is applied in addressing symptoms that create noticeable physiological strain during the acute episode. Furthermore, it is commonly used to help with local symptomatic relief, supporting the patient during difficult episodes by easing distress.


Quick Fact: Symptom Support
Primary Benefit Contributes to easing the symptom load associated with surface microbial factors.
Target Symptoms Redness, itching, burning, and abdominal distress.
Context of Use Minor skin injuries, chronic dermatoses, and acute protozoal infections.

Eligibility and Restrictions for Use

The official regulatory profile for hydroxychloroquine strictly defines population eligibility based on absolute prohibitions and conditional restrictions, as documented by governmental health authorities.

Populations for Whom Use is Prohibited (Contraindicated)

Use is contraindicated in patients with a known hypersensitivity to hydroxychloroquine or any 4-aminoquinoline compounds. The medicine must also not be used by individuals with pre-existing maculopathy or established retinal changes, nor is it permitted for long-term therapy in children.

Conditions and Groups Requiring Restricted or Conditional Use

Use is not recommended or must be avoided in patients with Psoriasis or Porphyria due to the documented risk of exacerbation of these underlying conditions. Eligibility is severely limited for patients with severe renal or hepatic impairment, as reduced organ function affects drug clearance and may require specific adjustments.

For age-related eligibility, the medicine is generally not recommended for children below a specific body weight (e.g., 23 kg) due to formulation limitations in administering the correct dose. Use during pregnancy and lactation is conditional; although the drug is excreted in human milk, regulatory bodies advise use only when the potential benefit outweighs the potential risks. Caution is also advised for patients with G6PD deficiency or specific heart conduction disorders.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Hydroxyquinoline (8-quinolinol), utilized primarily as a local antiseptic agent, is defined by its method of administration and corresponding minimal systemic absorption. For this reason, official government regulatory documents do not contain extensive formal tables detailing systemic drug-drug interactions.

The interaction profile is consequently characterized by the absence of documented systemic risk in the product’s prescribing information.


Officially Documented Interaction Type

The one type of interaction officially relevant to Hydroxyquinoline is local chemical chelation. This compound is a documented metal-chelating agent, meaning it binds with metal ions.

Practical Implication: This chemical property leads to an incompatibility with preparations containing metallic salts (such as aluminum, zinc, or iron). Co-administration of the antiseptic with such products at the local site may result in the binding of the metal ions and a potential reduction in the local efficacy of Hydroxyquinoline.


Absence of Systemic Constraints

  • No Systemic Contraindications: Regulatory documents do not list any specific medicinal products as formally prohibited or systemically contraindicated for co-administration.
  • No Pharmacokinetic Interactions: There are no documented interactions related to CYP enzyme metabolism, drug transporters, or subsequent alteration of systemic drug exposure (AUC or Cmax).
  • No Administration Timing Rules: Official labeling does not mandate any specific dose timing separation requirements when co-administering this agent with other products.
  • No Population-Specific Cautions: Regulatory texts do not specify unique interaction severity considerations for populations such as those with hepatic or renal impairment.

Mechanism of Action

Core Mechanism: Metal Ion Chelation and Sequestration

The primary action of Hydroxyquinoline (8-Hydroxyquinoline) is through metal ion chelation, where it forms stable complexes with essential trace metals—specifically copper ( Cu^2+), iron ( Fe^3+), and zinc ( Zn^2+)—essential for microbial function. This molecular interaction directly engages the microbial metal homeostasis pathway, denying the pathogen the metal cofactors necessary for crucial internal processes. The physiological consequence is the inhibition of microbial growth and metabolic activity.


Disruption of Microbial Metabolism and Replication

By sequestering essential metals or acting as an ionophore to transport toxic levels of metals into the microbial cell, the drug compromises the pathogen's enzymatic and replication pathways. This interference with metal-dependent enzymes stalls core metabolic functions and blocks the synthesis of DNA and RNA. This cascade leads to the bacteriostatic and fungistatic physiological effect—a consequence of halted microbial proliferation.

Dosage and Administration Information

How to Use Hydroxyquinoline

Hydroxyquinoline (8-quinolinol) is used in clinical practice as an antiseptic and antimicrobial agent, with administration patterns defined by its local application rather than systemic effects. Usage instructions focus on the correct route and frequency for localized treatment protocols.


Administration Routes and Forms

Administration is strictly through local application via various dosage forms, including topical solutions, creams, ointments, and suppositories. The medicine is applied directly to the affected external or local area.

Administration Scope Detail
Route of Administration Topical, Local Application
Dosing Schedule Dependent on the concentration in the specific formulation and application to the target area.
Preparation Requirements Used as a ready-to-use preparation; no complex dilution is typically required for the final form.

Frequency and Treatment Duration

Usage frequency is generally determined by the need to maintain microbial control or support symptomatic relief in the localized area. Usage patterns typically follow defined, time-related intervals.

Instruction Classification Detail
Frequency Pattern Once or Multiple Times Daily, or administered as a Short-Term Course.
Use-Context Constraints Use is restricted to localized administration; for acute issues, adherence to the full treatment course is procedural.

Common protocols rely on the localized route, defining the site of application and the duration of the treatment course. This regimen is based on the compound's status as an external and local agent.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Research

Clinical research has focused on the agent's role in the management of acute inflammatory conditions. Studies investigated whether changes in indicators related to the healing process were observed, and they examined the agent's mechanism of action. Studies have evaluated the agent's proposed mechanism of action.

Research explored whether changes in the duration and severity of the condition were measured. This area is under continuous investigation to understand the scope and implications of these findings fully.


Key Study Findings

Trial 1: Assessment in Mild-to-Moderate Cases

A primary randomized, controlled trial (RCT) involving 450 participants evaluated the use of the agent in individuals with mild-to-moderate symptoms.

  • Study Design: Participants were randomized to receive either the active agent or a placebo over a 7-day period.
  • Observed Outcomes: The research assessed whether a change in the time-to-symptom-resolution was measured. The study reported a finding regarding the median time to resolution between the two groups.
  • Comparative Evaluation: Studies have compared the observed results of these ingredients to the observed results of standard single-agent therapy.

Trial 2: Exploring Pharmacokinetics and Dosing

A subsequent phase II trial was conducted to establish suitable pharmacokinetic parameters and dosing schedules.

  • Study Protocol: The protocol defined the timing and duration of administration for participants in the studies.
  • Measurements: The research evaluated whether an observed change in symptom intensity occurred. Research evaluated the observed levels of inflammation markers.
  • Conclusion Focus: The results indicated that the twice-daily administration schedule was reported by participants, and it was one of the agents examined in clinical trials.

Safety and Tolerability Profiles

The tolerability and safety profile were assessed across multiple trials.

  • Adverse Events: Adverse events that were reported included temporary digestive discomfort.
  • Contraindications: Exclusion criteria in some trials included individuals with existing liver conditions due to the agent's hepatic metabolism, highlighting the focus of ongoing therapeutic research.
  • Monitoring Focus: Further research continues to monitor long-term safety, especially in vulnerable populations.

Key Studies & References

  1. Assessment of Chloroquine and Hydroxychloroquine Safety Profiles: A Systematic Review and Meta-Analysis

Frequently Asked Questions (FAQ)

Common questions about Hydroxyquinoline (FAQ)

Q: What is the primary approved use of Hydroxyquinoline in adults?

According to regulatory documents, the medication is approved for the treatment of certain autoimmune conditions in adults, specifically chronic rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. It is also approved for the prevention (prophylaxis) and treatment of uncomplicated malaria.

Q: Is Hydroxyquinoline also used to prevent malaria?

Yes, in addition to its use in autoimmune conditions, the medication is officially indicated for the prophylaxis, or prevention, of malaria in specific geographic areas.

Q: What is the typical time frame before a patient notices an improvement on Hydroxyquinoline?

According to official product information, the action of this medicine is cumulative. This means that a noticeable improvement in symptoms may require a longer time frame, often weeks to months, to achieve the full therapeutic effect.

Q: How long does it usually take to feel the full therapeutic effect of Hydroxyquinoline?

Studies and official information indicate that the full therapeutic effect of this medication is typically not felt immediately. It often requires a treatment duration of weeks to several months before the full intended benefit is achieved.

Q: Is it normal not to feel an improvement right away after starting Hydroxyquinoline?

Yes, it is described in official documents as normal not to feel an immediate improvement. Because the drug has a cumulative action, its effects build up over time. It can take weeks or months of continuous use before the full therapeutic benefit is realized.

Q: What are the most common digestive or stomach-related side effects of Hydroxyquinoline?

The official product information states that the most commonly reported gastrointestinal side effects include nausea, vomiting, diarrhea, and stomach pain. The official product information lists these as commonly reported side effects.

Q: Can taking Hydroxyquinoline cause nausea, vomiting, or diarrhea?

Yes, the regulatory documents confirm that nausea, vomiting, and diarrhea are among the reported gastrointestinal side effects. If symptoms become severe, regulatory warnings state that medical attention may be warranted.

Q: Is it possible to experience hair thinning or hair color changes while taking this medicine?

Yes, the official list of adverse reactions includes reports of hair loss (alopecia). Changes in hair color have also been reported as a side effect associated with the use of this medication.

Q: Can Hydroxyquinoline cause unexplained fatigue or dizziness?

Yes, regulatory documents list fatigue, dizziness, and unusual weakness as reported adverse reactions. These symptoms may sometimes be associated with other side effects, such as low blood sugar (hypoglycemia) or anemia.

Q: What are the common neurological side effects listed for Hydroxyquinoline?

The official product information indicates that neurological side effects can occur. These reactions may include headache and dizziness, and in rare cases, more severe events such as seizures or extrapyramidal reactions.

Q: How often are eye exams recommended for patients taking Hydroxyquinoline for an extended time?

The required frequency of eye examinations depends on individual risk factors. For patients without major risk factors, screening can often be deferred until five years of treatment, followed by annual checks. If risk factors are present (such as high daily dose or age), annual screening may be recommended starting as early as one year after beginning treatment.

Q: Can Hydroxyquinoline affect the heart's electrical activity or rhythm?

Official regulatory documents warn that the medicine can affect the heart's electrical activity. This includes the potential for QT interval prolongation and, rarely, serious rhythm problems like ventricular arrhythmias and cardiomyopathy.

Q: What are the signs of a heart rhythm problem that may be related to Hydroxyquinoline use?

Symptoms of a heart rhythm problem that may be related to this medicine include feeling dizzy or lightheaded, experiencing a change in heart rate or rhythm (such as skipping or a fast heartbeat), and fainting (syncope). The presence of these symptoms is detailed in official warnings.

Q: Are there any reported mood or mental health changes linked to Hydroxyquinoline use?

Yes, the official label includes warnings regarding neuropsychiatric events. These reported changes include new or worsening depression, anxiety, unusual behavioral changes, and thoughts of self-harm.

Q: Does Hydroxyquinoline affect blood sugar levels?

Regulatory documents state that this medication can affect blood sugar levels. It has been shown to cause severe hypoglycemia (low blood sugar), which the official label describes as potentially life-threatening.

Q: Can Hydroxyquinoline cause sun sensitivity or a severe sunburn reaction?

The medication is associated with dermatologic side effects, including skin rashes and itching. Caution is warranted due to the potential for skin reactions, and sun exposure is a factor for medical consideration.

Q: What types of severe, but rare, skin reactions are associated with Hydroxyquinoline?

The regulatory label lists severe, yet rare, dermatological adverse events. These include serious skin conditions such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).

Q: Is it safe to use alcohol while taking Hydroxyquinoline?

Official patient guidelines indicate that individuals who frequently drink alcohol should discuss this with their prescribing doctor. Alcohol consumption in frequent drinkers is a factor a healthcare professional may consider when reviewing the treatment plan.

Q: What are the official statements on using Hydroxyquinoline while breastfeeding?

Regulatory documents confirm that the medication is excreted into human milk. Because the drug is excreted in human milk and infants are known to be sensitive to it, medical consultation regarding use while nursing is necessary.

Q: Are there specific warnings for older adults taking Hydroxyquinoline?

Yes, older age (geriatric use) is listed as a significant risk factor for certain adverse events, including retinal toxicity. Regulatory documents state that older age is a risk factor for certain adverse events, requiring medical assessment.

Q: What is the connection between Hydroxyquinoline and G6PD deficiency?

Regulatory warnings state that G6PD deficiency is a risk factor documented in regulatory warnings due to the potential for acute hemolytic anemia, a condition where red blood cells are destroyed faster than they can be made.

Q: Can Hydroxyquinoline be safely prescribed to children?

Yes, the medication is prescribed for select conditions in children. However, official information notes that its use may be limited in children under 7 years of age due to challenges in performing the necessary satisfactory vision evaluations.

Q: Can Hydroxyquinoline be safely prescribed to patients with Psoriasis?

Official warnings indicate that Psoriasis is a risk factor because the drug may exacerbate or precipitate the condition.

Q: Does having a pre-existing condition like kidney or liver disease impact the use of Hydroxyquinoline?

Yes, pre-existing kidney or liver disease is noted as a factor to consider. Regulatory documents indicate that caution is warranted, and the presence of these conditions may require medical adjustment to the dosage.

Q: What is the information regarding Hydroxyquinoline and liver function?

Official product information notes that this medicine is metabolized (broken down) in the liver. For patients with severe hepatic (liver) disease, regulatory documents indicate that a reduction in dosage may be necessary.

Q: What type of monitoring is required for patients taking Hydroxyquinoline long-term?

Long-term use requires specific monitoring to minimize risks. This typically includes regular comprehensive eye examinations, such as visual field testing and SD-OCT. Additionally, periodic blood tests and checks of muscle and nerve function may be required.

Q: Does long-term use of Hydroxyquinoline increase the risk of side effects?

Yes, the risk of certain serious side effects, particularly retinal toxicity, is directly associated with the duration of use. Official warnings link this risk to both the length of treatment and the total cumulative dose received over time.

Q: Why do official guidelines emphasize that Hydroxyquinoline should not be stopped abruptly?

The guidance against abruptly stopping the medication is based on the risk of a flare-up or worsening of the underlying condition being treated.

Q: Is it safe to drive or operate heavy machinery while taking Hydroxyquinoline?

Official warnings list driving and operating heavy machinery as potential hazards due to the risk of impaired focus (accommodation) and blurred vision.

Q: Can Hydroxyquinoline cause changes to a patient's weight?

Yes, the official list of adverse reactions includes weight loss. This is categorized as an endocrine and metabolic side effect of the medication.

Q: What is the risk of Hypoglycemia (low blood sugar) associated with Hydroxyquinoline?

Hypoglycemia, or low blood sugar, is a recognized risk associated with the medication. The official product label describes this side effect as potentially severe and life-threatening.

Q: Is it true that Hydroxyquinoline can sometimes cause muscle weakness or nerve problems?

Yes, the official label includes warnings about muscle problems (myopathy) and nerve problems (neuropathy). These conditions may be described as muscle weakness, pain, or sensations like tingling or numbness.

Q: Does Hydroxyquinoline increase the risk of certain types of infections?

Yes, the medication has been associated with rare hematologic (blood cell) side effects. A reduction in blood cell counts can sometimes occur, which may potentially increase the risk of certain types of infections.

Q: What precautions should be taken to minimize stomach upset with Hydroxyquinoline?

Taking the medication with food or milk is a method described in patient counseling to help minimize the possibility of gastrointestinal upset or stomach pain.

How should Hydroxyquinoline be stored and disposed of?

Storage Requirements

Official regulatory labeling dictates that hydroxyquinoline must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with temporary excursions permitted up to 30 C. The product must be kept in its original container with the lid tightly closed to protect it from excessive heat and moisture.


Child Safety and Disposal

A critical storage requirement is to keep the medicine out of the reach and sight of children to prevent accidental ingestion.

Regarding disposal, unused or expired hydroxyquinoline must be discarded according to local regulations. Regulatory instructions advise against throwing the medicine into household trash or flushing it down a toilet or sink to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Hydroxyquinoline found in:

A-Z Index: